Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12820579 | 0.84 | HTT (0.46) | MEN1KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL12820642 | 0.81 | HSD17B10 (0.43) | KDM4EALDH1A1LMNAGLAPMP22 | |
| SCHEMBL10007309 | 0.76 | KDM4E (0.49) | KDM4EALDH1A1LMNAGLAPMP22 | |
| SCHEMBL12820769 | 0.74 | ALDH1A1 (0.47) | MEN1KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL12820641 | 0.72 | MEN1 (0.57) | MEN1KMT2AALDH1A1LMNAGAA | |
| SCHEMBL20646249 | 0.72 | PNP (0.37) | KDM4EALDH1A1LMNAGLAPMP22 | |
| SCHEMBL12820638 | 0.71 | SCN9A (0.56) | ALDH1A1HTTSMN1; SMN2TSHRMAPT | |
| SCHEMBL12958939 | 0.70 | DAO (0.50) | KDM4EALDH1A1LMNAGLAPMP22 | |
| SCHEMBL12820639 | 0.69 | MAOB (0.52) | ALDH1A1LMNAHTTSMN1; SMN2MAPT | |
| SCHEMBL1043887 | 0.69 | KDM4E (0.49) | KDM4EALDH1A1LMNAGLAPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120252791-A1 | Heterocyclic GTP Cyclohydrolase 1 Inhibitors For the Treatment of Pain | CHILDREN'S MEDICAL CENTER CORPORATION | 2012-10-04 | — | — | US | disclosed |
| US-20120252791-A1 | Heterocyclic GTP Cyclohydrolase 1 Inhibitors For the Treatment of Pain | CHILDREN'S MEDICAL CENTER CORPORATION | 2012-10-04 | — | — | US | disclosed |
| WO-2011035009-A1 | HETEROCYCLIC GTP CYCLOHYDROLASE 1 INHIBITORS FOR THE TREATMENT OF PAIN | HERCULES TECHNOLOGY MANAGEMENT CO V, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252791-A1 | Heterocyclic GTP Cyclohydrolase 1 Inhibitors For the Treatment of Pain | GGH, GGPS1, GGT1 | MEN1 4594/4885KMT2A 3807/4885KDM4E 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.